SCHEMBL3382735

SCHEMBL3382735

COc1cccc(C(=O)NCCc2c(C)[nH]c3ccccc23)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.63
MTNR1A P48039 2/20 0.59
MTNR1B P49286 2/20 0.59
KMT2A Q03164 5/20 0.59
MAPT P10636 8/20 0.57
TDP1 Q9NUW8 2/20 0.57
PABPC1 P11940 1/20 0.57
ALOX15 P16050 1/20 0.57
ALDH1A1 P00352 4/20 0.52
MEN1 O00255 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
HTT P42858 3/20 0.52
LMNA P02545 3/20 0.52
GAA P10253 2/20 0.52
ALOX12 P18054 2/20 0.52
USP2 O75604 1/20 0.52
HPGD P15428 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
PARP14 Q460N5 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384994 0.88 MAPT (0.68) ATMMTNR1AMTNR1BKMT2AMAPT
SCHEMBL7863760 0.85 MAPT (0.72) ATMMTNR1AMTNR1BKMT2AMAPT
SCHEMBL3230797 0.85 ATM (0.66) ATMKMT2AMAPTTDP1PABPC1
SCHEMBL3381318 0.83 MAPT (0.70) ATMKMT2AMAPTTDP1PABPC1
SCHEMBL3605297 0.82 ATM (0.65) ATMMTNR1AMTNR1BKMT2AMAPT
SCHEMBL3227065 0.81 MTNR1A (0.77) MTNR1AMTNR1BKMT2AMAPTTDP1
SCHEMBL3230209 0.80 ATM (0.69) ATMKMT2AMAPTTDP1PABPC1
SCHEMBL3384252 0.80 ATM (0.69) ATMKMT2AMAPTTDP1PABPC1
SCHEMBL3384793 0.80 ATM (0.69) ATMKMT2AMAPTTDP1PABPC1
SCHEMBL3384593 0.79 ATM (0.67) ATMKMT2AMAPTTDP1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor BAYER SCHERING PHARMA AG (DE) 2010-02-04 US claimed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP claimed
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor BAYER SCHERING PHARMA AG (DE) 2010-02-04 US disclosed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor PTGER2, PTGER1, PTGDR2 ATM 4060/4885MTNR1A 579/4885MTNR1B 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.